Publications 2016
MORGAND M, BOUVIN-PLEY M, PLANTIER JC, MOREAU A, ALESSANDRI E, SIMON F, PACE CS, PANCERA M, HO DD, POIGNARD P, BJORKMAN PJ, MOUQUET H, NUSSENZWEIG MC, KWONG PD, BATY D, CHAMES P, BRAIBANT M, BARIN F. A v1v2 neutralizing epitope is conserved in divergent non-m groups of hiv-1. J Acquir Immune Defic Syndr, 2016, 71, 237-245.
PREL A, CAVAL V, GAYON R, RAVASSARD P, DUTHOIT C, PAYEN E, MAOUCHE-CHRETIEN L, CRENEGUY A, NGUYEN TH, MARTIN N, PIVER E, SEVRAIN R, LAMOUROUX L, LEBOULCH P, DESCHASEAUX F, BOUILLE P, SENSEBE L, PAGES JC. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. Mol Ther Methods Clin Dev 2015, 2,e15039.
BEAUMONT E, ROCH E, CHOPIN L, ROINGEARD P. Hepatitis C virus E1 and E2 proteins used as separate immunogens induce neutralizing antibodies with additive properties. PLoS One 2016, 11, e0151626.
ROINGEARD P. Is hepatitis C virus eradication a realistic objective in the absence of a prophylactic vaccine ? Liver Int 2016, 36, 1076.
SILBERSTEIN E, ULITZKY L, ALVES LIMA L, CEHAN N, TEXEIRA CARVALHO A, ROINGEARD P, TAYLOR DR. HCV-mediated apoptosis of hepatocytes in culture and viral pathogenesis. PLoS One 2016 ; 11 : e0155708
GASSER R, HAMOUDI M, PELLICCIOTTA M, ZHOU Z, VISDELOUP C, COLLIN P, BRAIBANT M, LAGANE B, NEGRONI M. Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions. Retrovirology 2016, 13, 50.
KERVIEL A, DASH S, MONCORGE O, PANTHU B, PRCHAL J, DECIMO D, OHLMANN T, LINA B, FAVARD C, DECROLY E, OTTMAN M, ROINGEARD P, MURIAUX D. Involvment of an arginine triplet in M1 matrix protein interaction with membrane and in M1 recruitment into virus-like particles of the influenza A(HIN1)pdm09 virus. PLoS One 2016 ;11 :e0165421.
PREL A, CAVAL V, GAYON R, RAVASSARD P, DUTHOIT C, PAYEN E, MAOUCHE-CHRETIEN L, CRENEGUY A, NGUYEN TH, MARTIN N, PIVER E, SEVRAIN R, LAMOUROUX L, LEBOULCH P, DESCHASEAUX F, BOUILLE P, SENSEBE L, PAGES JC. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. Mol Ther Methods Clin Dev 2015, 2,e15039.
BEAUMONT E, ROCH E, CHOPIN L, ROINGEARD P. Hepatitis C virus E1 and E2 proteins used as separate immunogens induce neutralizing antibodies with additive properties. PLoS One 2016, 11, e0151626.
ROINGEARD P. Is hepatitis C virus eradication a realistic objective in the absence of a prophylactic vaccine ? Liver Int 2016, 36, 1076.
SILBERSTEIN E, ULITZKY L, ALVES LIMA L, CEHAN N, TEXEIRA CARVALHO A, ROINGEARD P, TAYLOR DR. HCV-mediated apoptosis of hepatocytes in culture and viral pathogenesis. PLoS One 2016 ; 11 : e0155708
GASSER R, HAMOUDI M, PELLICCIOTTA M, ZHOU Z, VISDELOUP C, COLLIN P, BRAIBANT M, LAGANE B, NEGRONI M. Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions. Retrovirology 2016, 13, 50.
KERVIEL A, DASH S, MONCORGE O, PANTHU B, PRCHAL J, DECIMO D, OHLMANN T, LINA B, FAVARD C, DECROLY E, OTTMAN M, ROINGEARD P, MURIAUX D. Involvment of an arginine triplet in M1 matrix protein interaction with membrane and in M1 recruitment into virus-like particles of the influenza A(HIN1)pdm09 virus. PLoS One 2016 ;11 :e0165421.